Geulah Livshits
Stock Analyst at Chardan Capital
(4.57)
# 287
Out of 5,031 analysts
225
Total ratings
52%
Success rate
29.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Maintains: Buy | $12 | $4.72 | +154.24% | 15 | Oct 17, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $11 | $3.71 | +196.50% | 22 | Oct 14, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Buy | $15 → $17 | $9.58 | +77.45% | 11 | Oct 7, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $60 → $73 | $73.15 | -0.21% | 3 | Sep 26, 2025 | |
| IMRX Immuneering | Maintains: Buy | $13 → $20 | $5.58 | +258.42% | 14 | Sep 26, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $219 → $216 | $190.23 | +13.55% | 13 | Aug 22, 2025 | |
| MGX Metagenomi | Maintains: Buy | $12 → $11 | $3.05 | +260.66% | 7 | Aug 15, 2025 | |
| SLDB Solid Biosciences | Maintains: Buy | $15 | $5.88 | +155.10% | 8 | Aug 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $25 | $9.84 | +154.07% | 12 | Aug 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $68 → $60 | $24.75 | +142.42% | 15 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $10 | $5.45 | +83.49% | 6 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 | $2.15 | +458.14% | 10 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $20 | $2.18 | +817.43% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $1.81 | +397.24% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 | $69.15 | +18.58% | 15 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 | $8.07 | +1,386.99% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.54 | +1,006.40% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.77 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $7.75 | +429.03% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $9.87 | +153.29% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.85 | +321.05% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $26.01 | +699.69% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $0.93 | +1,627.30% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $11.73 | +667.26% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $4.95 | -19.19% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $4.29 | +599.30% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $15.67 | +14.87% | 1 | Oct 27, 2020 |
Taysha Gene Therapies
Oct 17, 2025
Maintains: Buy
Price Target: $12
Current: $4.72
Upside: +154.24%
Rocket Pharmaceuticals
Oct 14, 2025
Maintains: Buy
Price Target: $11
Current: $3.71
Upside: +196.50%
Lexeo Therapeutics
Oct 7, 2025
Maintains: Buy
Price Target: $15 → $17
Current: $9.58
Upside: +77.45%
Palvella Therapeutics
Sep 26, 2025
Maintains: Buy
Price Target: $60 → $73
Current: $73.15
Upside: -0.21%
Immuneering
Sep 26, 2025
Maintains: Buy
Price Target: $13 → $20
Current: $5.58
Upside: +258.42%
Krystal Biotech
Aug 22, 2025
Maintains: Buy
Price Target: $219 → $216
Current: $190.23
Upside: +13.55%
Metagenomi
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $3.05
Upside: +260.66%
Solid Biosciences
Aug 14, 2025
Maintains: Buy
Price Target: $15
Current: $5.88
Upside: +155.10%
4D Molecular Therapeutics
Aug 12, 2025
Maintains: Buy
Price Target: $25
Current: $9.84
Upside: +154.07%
Intellia Therapeutics
Aug 11, 2025
Maintains: Buy
Price Target: $68 → $60
Current: $24.75
Upside: +142.42%
Aug 8, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $5.45
Upside: +83.49%
Aug 8, 2025
Maintains: Buy
Price Target: $12
Current: $2.15
Upside: +458.14%
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $2.18
Upside: +817.43%
Aug 7, 2025
Maintains: Buy
Price Target: $9
Current: $1.81
Upside: +397.24%
Aug 5, 2025
Maintains: Buy
Price Target: $82
Current: $69.15
Upside: +18.58%
Jun 24, 2025
Maintains: Buy
Price Target: $120
Current: $8.07
Upside: +1,386.99%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.54
Upside: +1,006.40%
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.77
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $7.75
Upside: +429.03%
Mar 23, 2023
Maintains: Buy
Price Target: $28 → $25
Current: $9.87
Upside: +153.29%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $2.85
Upside: +321.05%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $26.01
Upside: +699.69%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $0.93
Upside: +1,627.30%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $11.73
Upside: +667.26%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $4.95
Upside: -19.19%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $4.29
Upside: +599.30%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $15.67
Upside: +14.87%